The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals’ drug combination to treat the most common form of liver cancer.
Korean biotech HLB …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume
Early results of an international study examining the risk of arthritis for people with psoriasis have shown a high burden of joint symptoms in 712
A new study, published in Nature Communications this week, led by Jake Gavenas PhD, while he was a PhD student at the Brain Institute at